Progressing to study Radspherin® in the first-line treatment setting for ovarian cancer IND clearance is now obtained for both lead indications for Radspherin®

This marks the first IND clearance for initiation of Radspherin® clinical trials in the US

At 18 months, no patients at the recommended dose of 7 MBq experienced peritoneal recurrences Robust safety profile demonstrated, no serious adverse events related to Radspherin® reported Presentation on October 4, 2023, at 11:55 a.m. CET (5:55 a.m. EDT)

Recommended dose of 7 MBq established following completion of dose escalation; no dose-limiting toxicity observed Presentation on September 30, 2023

Anders brings nearly 30 years of international and diverse experience in oncology-focused drug development and commercialization.

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023, at 9:30 a.m. ET.

Median PFS (progression free survival) was not reached at 15 months, and no patients at recommended dose of 7 MBq had peritoneal recurrences All dose levels of Radspherin®, including recommended dose of 7 MBq, were well tolerated at 15 months with no serious adverse events related to Radspherin® reported Radspherin® is currently being evaluated in two ongoing Phase 1/2A trials for the treatment of peritoneal carcinomatosis from colorectal cancer and ovarian cancer Poster discussion session on June 5, 2023 at 1:15 p.m. ET

Publications highlight the safety and tolerability of Radspherin® for patients and those externally exposed to radiation, all dose levels were well tolerated with dose level toxicity (DLT) not reached.

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced strong progress with clinical trials, including patient recruitment and efficacy signals.  Further updates will be provided in an upcoming investor conference call.

First patient has been treated in the RAD-18-002 phase 2A clinical study